3m Innovative Properties Company

Coley Pharmaceutical Group, Inc.

Graceway Pharmaceuticals, LLC

Philip D Heppner

Bryon A Merrill

Kyle J Lindstrom

Tushar A Kshirsagar

Michael J Rice

Stephen L Crooks

Joseph F Dellaria, Jr

George W Griesgraber

John F Gerster

Shri Niwas

Chad A Haraldson

John W Mickelson

Joshua R Wurst

Gregory J Marszalek

Scott E Langer

Matthew R Radmer

Michael E Danielson

Gregory D Lundquist, Jr

Peter V Maye

William H Moser

David T Amos

Joan T Moseman

David S Hays

Maureen Ann Kavanagh

Sarah A Strong

Ryan B Prince

Bernhard M Zimmermann

Karl J Manske

Sarah J Slania

Doris Stoermer

Jason D Bonk

Luke T Dressel

John R Jacobsen

Leslie J Charles

Ralph R Roberts

Ai-Ping Wei

Byron A Merrill

Hugues M H Martin

Larry R Krepski

Daniel E Duffy

Azim Alan Celebi

Sarah Johannessen

David J Squire

Sarah C Johannessen

Sarah C Slania

Hugues Martin

Imidazoquinoline compounds with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.

Alkoxy substituted imidazoquinolines

Thiazoloquinolines and thiazolonaphthyridines with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines

Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, and prodrugs thereof, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Pyrazolopyridines and analogs thereof

A method of preferentially inducing IFN-&#x3b1; biosynthesis in an animal comprising administering certain imidazo[4,5-c] ring compounds with a hydroxymethyl or hydroxyethyl substituent at the 2-position or pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of using these compounds a immunomodulators for treatment of diseases including viral and neoplastic diseases comprising preferentially inducing IFN-&#x3b1; biosynthesis in an animal are disclosed.

Method of preferentially inducing the biosynthesis of interferon

Imidazo-containing compounds (e.g., imidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Oxime substituted imidazo-containing compounds

Imidazoquinolines and imidazonaphthyridines with a substituent containing a functional group, e.g., an amide, sulfonamide, urea, or heterocyclyl group, at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Substituted imidazoquinolines and imidazonaphthyridines

Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and imidazopyridines) with a hydroxylamine substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Hydroxylamine substituted imidazoquinolines

1H-Imidazo[4,5-c]quinolin-4-amines with a hydroxy, alkoxy, hydroxyalkoxy, or alkoxyalkoxy substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods

Thiazolo[4,5-c]ring compounds, (e.g. thiazolopyridine, thiazoloquinoline, 6,7,8,9-tetrahydrothiazoloquinoline, thiazolonaphthyridine, and 6,7,8,9-tetrahydrothiazolonaphthyridine compounds) having an oxime or hydroxylamine substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

[object Object]

Certain imidazonaphthyridines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-&#x3b1; biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Hydroxyalkyl substituted imidazonaphthyridines

Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Aryloxy and arylalkyleneoxy substituted imidazoquinolines

Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-&#x3b1; biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Hydroxyalkyl substituted imidazoquinolines

Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, and an aryl or heteroaryl substituent at the 7-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-&#x3b1; biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Hydroxyalkyl substituted imidazoquinoline compounds and methods

Growing community of inventors

Forest Lake, MN, United States of America

Philip D Heppner